[Follow-up of lung function and clinical outcomes of chest tightness variant asthma in school-age children and adolescent].

Authors

W J Zhu, J L Chen, L Sha, X Song, S Li, Q L Gu

Published in

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. Volume 60. Issue 6. Pages 876-884. Jun 06, 2026.

Abstract

Objective: To analyze the outcomes, risk factors and lung function changes after treatment among school-age children older than 6 with chest tightness variant asthma (CTVA). Methods: This study was a prospective cohort study including 130 CTVA children in outpatients from January 2021 to January 2023. 130 children recorded demographic data, clinical characteristics and examinations. 114 children were followed for one year, including 67 males and 47 females, with range of 6.08-15.33 years. Risk factors for poor remission of clinical symptoms in CTVA children were analyzed. Lung function data were collected for baseline, 6 months, and 12 months, and were compared through using repeated measurement analysis of variance measurement. Results: After 1 month of inhaled corticosteroids (ICS), 59.65% (68 cases)of CTVA children achieved complete clinical remission. Symptoms of nasal congestion (47.8%, 22/46 vs. 22.1%, 15/68, OR=3.96, 95%CI 1.45-10.81, P=0.007) and history of asthma in first-degree relatives (13.0%, 6/46 vs.1.5%, 1/68, OR=11.61, 95%CI 1.07-125.92, P=0.044) were independent risk factors for poor treatment response in CTVA. Regular us of ICS improved lung function parameters after 12 months: FEV₁%pred increased from baseline (99.18±12.97)% to (105.06±12.01)% at 12 months; PEF%pred increased from (88.30±13.53)% to (97.90±14.74)%; FEF₂₅%pred increased from (86.86±18.75)% to (96.58±18.57)%; FEF₅₀%pred increased from (78.58±23.32)% to (89.49±21.55)%; FEF₇₅%pred increased from (73.04±24.25)% to (82.59±25.49)%; and MMEF%pred increased from (79.93±23.85)% to (89.50±22.05)%. According to the variance analysis of repeated measurement, the interaction between groups and time had a statistically significant effect on the following lung function: FEV₁%pred (F=8.123, P<0.001), PEF%pred (F=9.605, P<0.001), FEF₂₅%pred (F=4.300, P=0.015), FEF₅₀%pred (F=4.174, P=0.017), FEF₇₅%pred (F=5.791, P=0.004), and MMEF%pred (F=4.648, P=0.011). Conclusion: After a short-term regularly using ICS treatment, over half of CTVA children can achieve completely clinical symptoms remission. The presence of nasal obstruction or a first-degree family history of asthma influence the clinical efficacy. Long-term regular use of ICS is beneficial for improving and maintaining lung function in CTVA children.

PMID:
42331526
Bibliographic data and abstract were imported from PubMed on 23 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.